C-JSCELinkGevity
Anti-Necrotics, necrosis inhibition, AI Blueprint Maps
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JSCE
C-JSCEC-JSCEAnti-Necrotics, necrosis inhibition, AI Blueprint Maps
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Watch all 2026 Global Conference session replays: https://milkeninstitute.org/events/global-conference-2026/program Scientific and technological advances are transforming our understanding of health, aging, and human biology in ways unthinkable just a decade ago. Regeneration, rejuvenation, peptides, reprogramming, and AI-enabled precision health now shape the longevity narrative, championed by voices ranging from fringe biohackers to wellness influencers to world-class physicians and scientists. Yet, this expansion of approaches, claims, and products has made it difficult for markets and consumers to discern what is ready for broad application from what is still emerging. New speculative interventions can also take the focus away from those proven to extend healthy life. As capital flows into the longevity space, how can markets distinguish promise from hype and translate credible science into investable, scalable solutions—while also clarifying what individuals can safely apply toda
The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF (http://bit.ly/3vTiACF). Famed short seller Andrew Left faces the possibility of decades behind bars after being found guilty of using disingenuous social media posts to manipulate stocks, in a landmark case that threatens to chill a broader trading strategy loathed by corporate executives. Left, who gained a large online following with his blunt commentary about major US companies as well as smaller stocks popular with retail traders, was convicted Monday following a three-week trial in Los Angeles. Even before his conviction, his 2024 indictment spooked the industry and led some short sellers to beef up legal disclaimers. Now, the 55-year-old faces more than two decades behind bars at an Aug. 31 sentencing hearing, though criminal defendants frequently get less time. Left will remain free until then. On this episode, Carol Massar and Tim Stenovec speak
It was once thought impossible to stop cell necrosis, but Dr. Carina Kern from LinkGevity is shattering the status quo. By analyzing the molecular blueprint of cell death, her team has developed a drug that shields cells from harsh conditions like hydrogen peroxide and limited oxygen and nutrients. In tests where 100% of cells typically die, this breakthrough kept 90% alive and viable. This robust data has been replicated by multiple contract research organizations, signaling a new era for longevity science and cellular health. #CellNecrosis #longevityscience #biohackingtips #healthoptimization #sciencediscovery
What if aging is not an inevitable decline but a solvable systems problem hiding in plain sight? Julian sits down with Carina Kern, a scientist working at the intersection of longevity research and medicine, for a wide ranging conversation on how aging actually works inside the body. Together, they explore why traditional medicine has struggled to address age-related decline and why treating one disease or one organ at a time may be missing the bigger picture. Carina introduces a systems level way of thinking about aging, explaining how cellular damage spreads across the body and why identifying key biological nodes could change how we prevent degeneration altogether. Julian and Carina also dive into Carina’s research on necrosis, a form of uncontrolled cell death that may sit at the core of aging and many chronic diseases. Carina explains how her team is developing a first in class anti necrotic therapy, how artificial intelligence is being used to uncover system wide interventions
Dr Carina Kern and Serena Kern-Libera joined Sophy Ridge and Wilfred Frost on their Sky News breakfast show to our Anti-Necrotic drug The Blueprint Theory of Ageing, developed by Dr Kern, is a new way of understanding why our cells and organs start to fail as we get older, giving rise to a range of diseases from Alzheimer’s to cardiovascular conditions. Dr Kern explains how her team uncovered a key biological “node” in these cascades of change called necrosis- a process where cells break down in a chaotic way- and how stopping it could help protect our organs from deterioration and extend healthy life.
#YoutubeShorts from @ProgressPotentialPossibilities Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging - https://www.youtube.com/watch?v=z4rf2Pbm2FM #CarinaKern #LinkGevity #BlueprintTheoryOfAging #BiologicalResilience #UniversityOfCambridge #BabrahamResearchCampus #CellularDegeneration #NecrosisInhibitor #AntiNecrotic #CaenorhabditisElegans #UCLInstituteOfHealthyAgeing #Senescence #Apoptosis #CellDeath #Necroptosis #Pyroptosis #Ferroptosis #PathoPathways #Gerotherapeutics #RyanodineReceptorInhibitors #CellPermeantCalciumChelators #LINK001 #AcuteKidneyInjury #SpaceMedicine #Exposome #Longevity #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
We joined Sophy Ridge and Wilfred Frost on their Sky News breakfast show to discuss LinkGevity and our Anti-Necrotic drug
Dr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI. Dr. Kern’s labs are based at the Babraham Research Campus, affiliated with the University of Cambridge and her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with UK Government, Francis Crick Institute KQ labs, and European Union (Horizon) support. The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizi
Discover the hidden biology behind how our bodies age over time - and the cutting-edge therapies that could transform the process. This lecture was recorded at the Ri on 11 October 2025. Join this channel as a Science Supporter to get access to perks: https://www.youtube.com/channel/UCYeF244yNGuFefuFKqxIAXw/join Subscribe for regular science videos: http://bit.ly/RiSubscRibe Watch the Q&A here (exclusively for our Science Supporters): https://youtu.be/9k6BS0FmSC4 Carina introduces the Blueprint Theory of Ageing, a new way of understanding why our cells and organs start to fail as we get older, giving rise to a range of diseases from Alzheimer’s to cardiovascular conditions. She explains how her team uncovered a key biological “node” in these cascades of change called necrosis- a process where cells break down in a chaotic way- and how stopping it could help protect our organs from deterioration and extend healthy life. This talk unpacks the latest research and challenges the way we
📚 인간 노화 억제·역노화 연구 성과 논문(학술지) 및 공식 보도자료·언론 출처 🧬 2025년 현재 역노화 연구 성과 및 과학계 소식 ✅ 1. 인간 대상 임상시험 – NAD+ 전구체 (Nicotinamide Riboside, NR) 연구기관: Chiba University, 일본 대상: 조로증 환자 (Werner Syndrome) 성과: NR 보충은 NAD+ 수치 증가, 심혈관 기능 개선, 피부 궤양 감소, 신장 보호 효과 확인 출처: Oshima J. et al., Nature Aging (2025). ScienceDaily 보도자료 ✅ 2. AI 기반 장수 약물 발굴 연구기관: Scripps Research & Gero (Alexey Moskalev, Michael Petrascheck 팀) 실험 대상: C. elegans (선충) 성과: 22개 후보 물질 중 16개가 수명 연장, 한 후보는 수명 74% 증가 출처: Artem Kaznatcheev et al., Nature Aging (2025). Scripps 공식 발표 ✅ 3. Senolytics (노화세포 제거제) 임상 기관: Mayo Clinic, University of Minnesota 등 대상: 노화세포 축적 관련 허약증( frailty ) 환자 성과: 초기 임상에서 운동능력 향상, 염증 수치 감소 보고 출처: Justice JN et al., The Lancet Healthy Longevity (2023). Nature Reviews Drug Discovery, 2024 ✅ 4. 항괴사제(Anti-necrotics) – 세포 괴사 억제 신약 후보 개발진: LinkGevity (Carina Kern) 성과: 체외 실험에서 괴사 억제율 90% 이상, 2025년 말 임상 예정 적용 가능성: 만성 염증, 신장질환, 알츠하이머 등 출처: Kern C. et al., Cell Death & Disease (2024). Popular Mechanic
This week, we have conversations with Sean MacDonald, CEO of Domain Therapeutics, Carina Kern, CEO and founder of LinkGevity, and Nadia Harhen, general manager of AI Simulation at SandboxAQ. Interview times: 03:41 Domain Therapeutics 27:14 SandboxAQ 48:04 LinkGevity Domain Therapeutics Domain Therapeutics is delivering breakthrough GPCR-targeting therapies in immuno-oncology and inflammation. Domain recently shared first-in-human results for EP4 antagonist DT-9081 (tumour-growth inhibition + clear RP2D), new pre-clinical detail on Treg-depleting anti-CCR8 mAb DT-7012, and breakthrough findings showing their PAR2 biased NAM can re-programme macrophages and restore checkpoint-blockade sensitivity. The highly differentiated and competitive properties of DT-7012 differentiate it from other clinical anti-CCR8 candidates, positioning it as a promising therapeutic solution to overcome immune evasion mechanisms and enhance anti-tumour immune responses in solid tumours. These preclinical fin
What Will Health Look Like in 50 Years? | Serena Kern-Libera on Ageing, Innovation & Hope What if everything we know about ageing — and how we treat it — changes within our lifetime? In this thought-provoking video, we ask Serena Kern-Libera, COO of Linkgevity, what she believes health will look like 50 years from now. Her answer dives deep into the future of healthcare, the fear of death, and how today’s systems treat ageing as a disease instead of a natural, addressable process. Together with her sister, Serena co-founded Linkgevity to challenge outdated treatment models. Her sister’s pioneering Theory of Ageing proposes a bold new framework — one that could redefine how we live, age, and thrive. Serena envisions a future where hospitals and healthcare systems focus on prevention, longevity, and dignity — not just disease management. This is more than biotech. This is about rewriting the future of human health. What kind of future will you help create? Explore the #BIGIMPACT of
LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease. Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural NASA Space-H Accelerator program, and how medicine can support human deep-space missions. LinkGevity was selected for the program, which is in its inaugural year. LinkGevity was selected as its research has uncovered technology with significant potential to minimize the health and performance risks in human spaceflight. LinkGevity’s anti-necrotics applications cover four major areas: organoid preservation and growth; cryopreservation; organ growth and preservation; and kidney protection. LinkGevity’s novel proprietary Blueprint Theory of Aging, developed by Kern, offers a multi-disciplinary framework for understanding the development o
Sponsored by Zenzero TechBio is impacting the drug discovery and development process in different ways. Along with a showcase of companies leveraging cutting edge data-driven techniques, our session will tackle the question of whether the outcomes are indeed better featuring: Keynote presentation: Empowering FAIR Data Practices with CDD Vault: Bridging Automation and Digitalisation in Research – Susana Tomasio, Collaborative Drug Discovery Pitches from two exciting companies to watch: Naveen Kaushik, Zenzero, Carina Kern, LinkGevity Panel discussion: Moderator: Rowan Gardner, PrecisionLife Panellists: Carina Kern, LinkGevity, Cam Watson, Nuclera, Naveen Kaushik, Zenzero, Susana Tomasio, Collaborative Drug Discovery
LinkGevity understands how necrosis is key to slow ageing | Dr. Carina Kern LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agree
Drug discovery company LinkGevity has been selected for The Francis Crick Institute’s KQ Labs Programme. The AI-driven company, based at Babraham Research Campus, Cambridge, is focused on age-related… | Business Weekly newspaper LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update yo
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's disease
LinkGevity | | The Pharmaletter Tuesday 2 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene Therapy Confere … herapeutic is a first-in-class Anti-Necrotic, which has earned a Horizon Europe grant from the European Union alongside UK government funding. LinkGevity was also selected as one of only 12 companies globally for the NASA/Microsoft Space-Health Program, due to the Anti-Necrotic’s potential in preventing accelerated aging and tissue degeneration in astronauts. The company plans to initiate a flagship clinical trial later in 2025, on the treatment of tissue degeneration in the
LinkGevity discusses anti-necrotic drug with BBC News | Lukasz Rzeczkowski posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … sformative therapies to patients requires clear regulatory insight. Our experts apply scientific rigor and global experience to navigate complex pathways, turning challenges into strategic milestones that advance development with confidence. Learn more: https://lnkd.in/ewZ25vEH . Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Merck 2,730,963 followers 4mo Report this post Our One Pipeline strategy means we follow the science –whether it comes fr … apital discipline, execution risk, and what the market is really being asked to fund at this stage. Read here: https://lnkd.in/gpPHj5-V View C2PA information Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Venturefest South 1,780 followers 4mo Report this post Biofilms might be microscopic, but their impact is anything but small 🧬 In our Meet the Partner blog, we explore the work of the National Biofilms Innovation Centre (NBIC) and how biofilm
Base to Base biotech podcast 16: Domain Therapeutics, SandboxAQ and LinkGevity | Podcast Episode on RSS.com You are using an old version of Internet Explorer, which is not supported any more by Microsoft. To fully take advantage of our service, we recommend to user a modern browser, such as Google Chrome . Sign up free Features Podcast Hosting Launch Your Podcast into the Stratosphere Podcast Analytics Navigate Your Podcast Analytics with Ease Distribution Distribute Your Podcast Across the Galaxy Monetization Turn Your Podcast into a Cosmic Cash Flow AI Transcription Boost the Visibility and
Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Base to Base biotech podcast 16: Domain Therapeutics, SandboxAQ and LinkGevity | LinkGevity LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linke
Dr. Carina Kern - CEO, LinkGev... - Progress, Potential, and Possibilities Podcast / Show - Apple Podcasts Zoek Home Nieuw Hitlijsten Zoek 23 november 2025 55 min. Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging Progress, Potential, and Possibilities Podcast / Show Speel af Send us Fan Mail Dr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integra
Carina Kern — Grokipedia Search ⌘K Suggest Edit Sign in Sign in Early life and education Childhood and family background Academic training and degrees Professional career Academic positions Industry roles and leadership Research contributions Early research in genetics and aging Recent research in biotechnology and space biology Biotechnology entrepreneurship Founding and leading LinkGevity Innovations in AI-driven drug discovery Public engagement and awards Media appearances and outreach Recognitions and honors References Fact-checked by Grok 4 months ago Carina Kern Ara Eve Leo Sal 1x Carina … n the molecular mechanisms of aging and chronic disease in genetic models. This fellowship solidified her expertise in evolutionary genetics and laid the groundwork for her subsequent research in biotechnology. [5] [6] Professional career Academic positions Carina Kern completed her PhD in genetics and evolutionary biology at University College London (UCL) before taking on a postdoctoral research fellow position at the UCL Institute of Healthy Ageing in 2021, where she inves … microgravity, drawing on her interdisciplinary background to promote innovative grant expansions through Innovate UK and UKRI. [13] Research contributions Early research in genetics and aging During her PhD at University College London's Institute of Healthy Ageing, Carina Kern investigated the genetic and evolutionary underpinnings of aging in the nematode Caenorhabditis elegans , focusing on how reproductive processes drive post-reproductive decline. Her thesis, "Agein … into practical therapeutics that she identified during her PhD and postdoctoral fellowship at University College London's Institute of Healthy Ageing. [5] Kern's work highlighted the limitations of model organism studies, such as those using Caenorhabditis elegans , in addressing human age-related diseases, prompting her to establish a company focused on bridging this divide through innovative biotechnology. [5] LinkGevity's mission centers on AI-powered drug discovery to tar … eutics that address multimorbidity and extend healthspan. [24] Central to BPT's application in AI-driven drug discovery is LinkGevity's proprietary platform, which employs semantic processing of vast biomedical datasets to generate Blueprint Maps—interactive visualizations of aging triggers from molecular to organismal scales. These AI models pre
New paper on systemic therapeutics for aging and medicine by LinkGevity | LinkGevity posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig
LinkGevity featured in FT's ageing science series, alongside Calico and others | Dr. Carina Kern posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu … e Lagier Tourenne first opened her lab at Mass General, her very first research grant came from Target ALS. A decade later, she’s once again at the forefront, this time as part of a collaborative consortium tackling one of the greatest mysteries in #ALS : sporadic ALS, which accounts for 90% of all cases. Now joined by Drs. Isaac Chiu , Brian Wainger, and Mark Albers, her team is uncovering how neurons’ own immune pathways may drive ALS progression, opening the door to entire
Overcoming the Impossible: LinkGevity's Breakthrough in #Necrosis Blocking | Dr. Carina Kern posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
GtR Home About this system Release history Contact us 📣 Help Shape the Future of UKRI's Gateway to Research (GtR) We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email [email protected] . Revolutionising Organ Preservation: Innovative Anti-Necrotic Technology for Enhanced Viability and Equity in Transplantation Lead Participant: LINKGEVITY LIMITED G … Reference: 10137928 Research Topic: Unclassified Lead Participant Project Cost Grant Offer LINKGEVITY LIMITED £333,416 £ 233,392 People ORCID iD Serena Kern-Libera (Project Manager) Publications The following are buttons which change the sort order, pressing the active button will toggle the sort order Author Name descending (press to sort ascending) Title Publication Date Published 10 25 50 --> --> Data The Data on this website provides information about publica … ; APIs A set of REST API's enable programmatic access to the data. Refer to the application programming interfaces GtR and GtR-2 Contact UKRI Gateway Polaris House Swindon SN2 1ET [email protected] Privacy  | Terms of Use   | OGL Data last updated: 14 Apr 2026  
LinkGevity Home About Us Pipeline News & Publications Contact Us Extending Healthspan With AI-Driven Drug Discoveries At the Frontier of Longevity Science: Pioneering Anti-Necrotics™ and Beyond Focus & Mission We believe that aging is triggered Our Vision is to increase healthspan and end the indignity of the downward spiral in health as we age. Our Mission is to locate and intervene in the biological triggers of aging. At LinkGevity, we are at the forefront of unravelling the mysteries of aging through our innovative approach of building Blueprint Maps. Rooted in our proprietary Bluep
Stebbing and the Necromaniac Sisters – For Better Science For Better Science By Leonid Schneider, on research integrity, biomedical ethics and academic publishing Menu About For Better Science and Contact Support my site! Comments Policy COVID-19 Macchiarini’s trachea transplant patients: the full list Smut Clyde Schneider Shorts Search Search for: Menu Search For Better Science Close Search for: About For Better Science and Contact Support my site! Comments Policy COVID-19 Macchiarini’s trachea transplant patients: the full list Smut Clyde Schneider Shorts Category Cloud Academic Publis … planned cell death involved in a range of age-related conditions. It has won an award from Innovate UK, and funding from the Horizon Europe science programme and the Francis Crick Institute, one of Europe’s biggest biomedical laboratories. It is one of several firms competing to license the first anti-ageing drug, described as a “holy grail” of the pharmaceutical world.” These Indian-Swiss sisters are Carina Kern , CEO of LinkGevity and former biology graduate at UCL, a … edical practice procedures in several clinics. These include asking patients to fund their own treatment using expensive immunotherapy drugs beyond the remit of their licence, supervising chemotherapy regimes “outside his area of expertise” and adopting a “gung ho approach” to patient care and management” Thing is, Stebbing’s patients were immensely rich yet terminally ill celebrities (including Roger Moore) and industrialists, and some, like New Zealand brewing m … an is particularly susceptible to necrosis and ageing. The firm could initially apply for the drug to be licensed for kidney disease and later submit an application for it to be approved as an anti-ageing drug.” A March 2025 press release announced an Innovate UK Smart Grant to Linkgevity for “ a one-year project involving the company’s Anti-Necrotic™ technology, specifically around acute tubular necrosis (ATN), which is a leading cause of kidney dysfunction ̶ … cine microbiology misconduct nanotechnology Nature neurology neuroscience Nobel Prize nutrition open access Paolo Macchiarini paper mills pharmacology Philipp Jungebluth physiology plagiarism plant sciences politics predatory publishing Pseudoscience psychology racism regenerative medicine retraction Russia Russia's War on Ukraine sexual har
LinkGevity Partners with NHS for Anti-Ageing Breakthrough | LinkGevity posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
Huge congratulations to LinkGevity’s phenomenal Chief Technology Officer Nikodem Grzesiak for being featured in Forbes 30 under 30! | Serena Kern-Libera LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedI
News & Updates | LinkGevity Home About Us Pipeline News & Publications Contact Us News & Publications Explore our news and publications to discover groundbreaking research, innovative drug developments, and insightful analyses on aging and longevity. Follow our journey as we share updates and breakthroughs. Latest highlights LinkGevity in the news Browse a curated feed of milestones, research updates, and media coverage December 5, 2025 LinkGevity on BBC News discussing the first Anti-Necrotic longevity drug BBC News program AI Decoded features our founders, Dr. Carina Kern and Ser
Carina Kern | SynBioBeta Speaker Γ SynBioBeta Speaker Carina Kern CEO LinkGevity Dr. Kern is the CEO of LinkGevity, an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. With a distinguished background in Molecular Biology, Pharmacology, Evolutionary Biology, and Genetics, she is renowned for her pioneering work on aging mechanisms and lifespan extension. Her labs are based at the Babraham Research Campus, affiliated with the University of Cambridge, UK. Her research has led to the development of a first-in-class necrosis inhibitor targeting cellular
Carina Kern - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Early research 2 Recent research 3 References Toggle the table of contents Carina Kern Add languages Add links Article Talk English Read Edit View history Tools Tools move to sidebar hide Actions Read Edit Vi … t News, Opinions, Analysis and Research . Retrieved 2025-04-02 . ^ "Innovate UK grant is boost for LinkGevity's anti-ageing mission" . Cambridge Independent . 2025-03-06 . Retrieved 2025-04-02 . ^ "Linkgevity targets aging as it joins startup accelerator KQ Labs | BioWorld" . www.bioworld.com . Retrieved 2025-04-02 . ^ "LinkGevity secures place in the SPACE-H accelerator program – SatNews" . news.satnews.com . Retrieved 2025-04-02 . ^ Kern, Carina; Bonventre, Joseph V.; Justi … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Carina Kern Add languag
About Us | LinkGevity Home About Us Pipeline News & Publications Contact Us About Us At LinkGevity, we are at the forefront of longevity science, dedicated to extending healthspan and improving quality of life through innovative drug discovery and advanced AI technology science Blueprint Theory of aging At LinkGevity, we embrace a pioneering approach to aging. Spearheaded by our CEO, Dr. Carina Kern, the Blueprint Theory provides a transformative framework illuminating the intricate "triggers" underlying aging and deterioration. By leveraging the power of the Blueprint, we uncove … fering unprecedented insights into the mechanisms that shape the aging process. APPLICATION Finding new drug classes At LinkGevity, our groundbreaking discovery of Anti-Necrotics™ marks a monumental leap forward in our quest to redefine the boundaries of health and longevity. By inhibiting necrosis, we are not only enhancing cellular resilience and fortifying cells against stress, but also paving the way for game-changing treatments in the clinic, starting with Acute Kidney I